Bayer reports strong pharma sales
Bayer AG (Xetra:BAYN) raised its 2013 pharmaceuticals sales guidance on Wednesday after reporting "better than anticipated" 2Q13 pharmaceutical sales. Sales in the segment rose 6% to EUR 2.8 billion ($3.7 billion) from EUR 2.7 billion ($3.4 billion) in 2Q12, driven by increased sales of cardiovascular drug Xarelto rivaroxaban. Xarelto sales were EUR 219 million ($284 million), a 222% boost from EUR 68 million ($86 million) in 2Q12.
Sales of ophthalmic drug Eylea aflibercept were EUR 73 million ($95 million) in 2Q13 and EUR 122 million ($158 million) for the first half. Bayer has ex-U.S. rights to the product from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN). Gastrointestinal cancer drug Stivarga regorafenib recorded EUR 47 million ($61 million) for the quarter and EUR 87 million ($113 million) for the half. ...